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structure, function and connections. Major advances in the understanding of neuroplasticity have to date yielded few established
interventions. To advance the translation of neuroplasticity research towards clinical applications, the National Institutes of
Health Blueprint for Neuroscience Research sponsored a workshop in 2009. Basic and clinical researchers in disciplines from
central nervous system injury/stroke, mental/addictive disorders, paediatric/developmental disorders and neurodegeneration/
ageing identiﬁed cardinal examples of neuroplasticity, underlying mechanisms, therapeutic implications and common denom-
inators. Promising therapies that may enhance training-induced cognitive and motor learning, such as brain stimulation and
neuropharmacological interventions, were identiﬁed, along with questions of how best to use this body of information to reduce
human disability. Improved understanding of adaptive mechanisms at every level, from molecules to synapses, to networks, to
behaviour, can be gained from iterative collaborations between basic and clinical researchers. Lessons can be gleaned from
studying ﬁelds related to plasticity, such as development, critical periods, learning and response to disease. Improved means of
assessing neuroplasticity in humans, including biomarkers for predicting and monitoring treatment response, are needed.
Neuroplasticity occurs with many variations, in many forms, and in many contexts. However, common themes in plasticity
that emerge across diverse central nervous system conditions include experience dependence, time sensitivity and the import-
ance of motivation and attention. Integration of information across disciplines should enhance opportunities for the translation
of neuroplasticity and circuit retraining research into effective clinical therapies.
Keywords: neuroplasticity; retraining; therapeutics; clinical assessment
Introduction
Twenty-seven leading scientists participated in a 2009 workshop
sponsored by the National Institutes of Health Blueprint for
Neuroscience Research, organized to promote opportunities for
the translation of neuroplasticity and circuit retraining research
into effective clinical therapies. Included were experts in neuro-
trauma and stroke, mental and addictive disorders, paediatric
and developmental disorders and neurodegeneration and ageing.
The participants identiﬁed cardinal examples of human neuroplas-
ticity in these conditions, underlying biological substrates and
mechanisms, promising interventions for promoting adaptive
neuroplastic changes and measures for evaluating neuroplastic
capacity and monitoring circuit engagement and reorganization.
The current report surveys neuroplastic adaptations across clinic-
al phenotypes and highlights a number of broad themes and po-
tential future directions that may produce therapeutic
interventions to reduce disability across a range of conditions
(Fig. 1).
Neuroplasticity can be broadly deﬁned as the ability of the ner-
vous system to respond to intrinsic and extrinsic stimuli by reor-
ganizing its structure, function and connections; can be described
at many levels, from molecular to cellular to systems to behaviour;
and can occur during development, in response to the environ-
ment, in support of learning, in response to disease, or in relation
to therapy. Such plasticity can be viewed as adaptive when asso-
ciated with a gain in function (Cohen et al., 1997) or as maladap-
tive when associated with negative consequences such as loss of
function or increased injury, points illustrated by animal models
and some human studies (Nudo, 2006). Also, adaptive plasticity
should be distinguished from compensatory behaviours, which are
behaviours that arise from mechanisms different from those op-
erative in the distributed neural networks that typically support
behaviour prior to disease onset (Levin et al., 2009).
Examples of neuroplasticity in the
clinical context
Injury: stroke, trauma and spinal cord injury
Among syndromes of human CNS injury, an area in which neu-
roplasticity has been extensively studied, is motor recovery after
stroke. Motor deﬁcits are present in a majority of patients with
stroke (Rathore et al., 2002), and the degree of motor recovery
can vastly inﬂuence whether or not the stroke proves disabling.
This is perennially a problem of major proportions—by some esti-
mates, 55–75% of stroke survivors still have functional limitations
and reduced quality of life months after the infarct (Levin et al.,
2009).
Studies of motor recovery after stroke illustrate the principle that
many forms of neuroplasticity can be ongoing in parallel. Injury to
a region of the motor network can result in spontaneous
intra-hemispheric changes, such as in representational maps, e.g.
the hand area can shift dorsally to invade the shoulder region
(Nudo et al., 1996; Muellbacher et al., 2002) or face region
(Weiller et al., 1993; Cramer and Crafton, 2006). At the same
time, the inter-hemispheric balance can shift such that the unin-
jured hemisphere has supranormal activity in relation to movement
(Chollet et al., 1991; Murase et al., 2004). Focal injury results in
diffuse adaptive changes (Brion et al., 1989), including changes in
the connections between network nodes (Grefkes et al., 2008;
Sharma et al., 2009b). The molecular basis of such spontaneous
adaptive changes includes a host of growth-related processes that
evolve over time (Nudo, 1999; Cramer and Chopp, 2000;
Carmichael et al., 2005; Wieloch and Nikolich, 2006). Similar re-
sults have been described in post-stroke recovery from non-motor
deﬁcits such as neglect (Corbetta et al., 2005) and language
(Rosen et al., 2000; Saur et al., 2006), though these rely on net-
works that are differently distributed as compared with the motor
system (Raymer et al., 2008). Cognitive recovery after stroke has
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i.e. the remote depression of function in non-injured tissue
(Munoz-Cespedes et al, 2005; Baillieux et al., 2010). Restorative
and rehabilitation post-stroke therapies produce a range of brain
events (Buma et al., 2010) that in many instances are similar to
those arising during spontaneous recovery from stroke, such as a
return to a normal degree of laterality (Fig. 2). Other changes can
be unique to therapy, such as new projections from neurons on
the undamaged side of the brain to denervated areas of the mid-
brain and spinal cord (Chen et al., 2002a). In some cases, the
behavioural signiﬁcance of such changes is understood—a shift
in inter-hemispheric balance towards the uninjured hemisphere is
the sign of a distressed system. In other cases, the exact behav-
ioural signiﬁcance of a pattern of post-stroke plasticity remains
unclear, such as the direction of somatotopic map shift after
focal cortical injury. As such, biomarkers of adaptive plasticity
(Milot and Cramer, 2008), such as those derived from transcranial
magnetic stimulation and functional MRI (Fig. 2), often have to be
narrowly deﬁned in relation to the targeted outcome. For ex-
ample, a measure of brain plasticity after stroke might have very
different signiﬁcance at different time points or after different
therapies (Dobkin, 2005). Other factors suggest the need for cau-
tious interpretation of brain plasticity measures after stroke. In
some cases, a stroke can affect brain function in ways outside
of study hypotheses. For example, in a patient with stroke, func-
tional MRI of the language system might be affected by reduced
attention; or transcranial magnetic stimulation, by abnormal rest-
ing tone or by excess force execution. Interpretation of functional
neuroimaging data always requires great care—after stroke this is
all the more true, as multiple brain systems and behaviours are
often affected (Krakauer, 2006).
Similar forms of adaptive neuroplasticity have been described
following other forms of acute CNS injury such as traumatic
brain injury (Munoz-Cespedes et al., 2005; Belanger et al.,
2007) and spinal cord injury (Topka et al., 1991; Cramer et al.,
2005; Rosenzweig et al., 2010). Interestingly, after spinal cord
injury, treatment-induced brain plasticity can be measured in the
absence of behavioural change (Cramer et al., 2007b). Such data
provide insight into the status of motor cortex function and might
be helpful for stratifying patients for treatments, such as stem cell
injections aimed at restoring voluntary motor control in patients
with dense plegia after spinal cord injury. The similarity of plasti-
city mechanisms across divergent forms of CNS injury suggests
that plasticity, as with development, uses a limited repertoire of
events across numerous contexts.
Another principle is that not all plasticity has a positive impact
on clinical status—in some cases, plasticity might have negative
consequences. For example, new onset epilepsy is a common
complication of cerebral trauma, often arising months to years
after the insult. This delayed onset suggests that progressive
changes in the brain, such as axonal sprouting and the formation
of new connections, produce alterations in neuronal signalling and
disinhibition that result in the induction of seizures (Prince et al.,
2009). Other examples suggestive of maladaptive plasticity include
chronic pain and allodynia following injury to a limb (such as am-
putation) or to CNS (dorsal spinal cord or thalamus), dystonia after
various CNS injuries and autonomic dysreﬂexia after spinal cord
injury (Karl et al., 2001). Thus, recovery from trauma or disease
Figure 1 Conceptual overview of the relationship between clinical phenotypes, neuroplasticity, therapeutic interventions and assessment
of function.
Harnessing neuroplasticity Brain 2011: 134; 1591–1609 | 1593Figure 2 Studies of the upper extremity motor system after stroke illustrate a number of forms of brain plasticity. (A–D) Brain plasticity
associated with spontaneous recovery. Several patterns of change arise spontaneously during the weeks following stroke onset. Laterality
is reduced. Normally, unilateral arm movement is associated with activity mainly in the contralateral hemisphere, but after a stroke, activity
is often seen in both hemispheres. Activity also increases in multiple brain areas throughout the motor network. These two points are
demonstrated in A by Fujii and Nakada, (2003), who used functional MRI and found that right hand grasping movements produced
predominantly left motor cortex activation in a healthy control; but in a typical patient with right hemiparesis, these movements were
associated with a shift in motor cortex laterality towards the right hemisphere (double arrow) as well as increased recruitment of left dorsal
premotor cortex (single arrow) and bilateral supplementary motor area (arrowhead). These patterns occur along a gradient. Thus, in
general, the poorer the behavioural outcome, the more these two mechanisms are invoked. For example, (B) shows data from Ward et al.
(2003). Across 20 patients, those with poorer recovery were more likely to recruit a number of bilateral motor-related brain regions over
and above those seen in the control group during a functional MRI grip task by the paretic hand, whereas patients with more complete
recovery were more likely to have a normal pattern of brain activation. Consistent with this (C), a poorer behavioural outcome is
associated with a smaller volume of excitable motor cortex. Thickbroom et al. (2004), who used transcranial magnetic stimulation, found a
linear relationship between the paretic hand’s grip strength and the size of its motor cortex map, each measure expressed as a ratio of
values from the contralesional side. Another pattern of spontaneous post-stroke plasticity is a shift in the location of primary sensorimotor
cortex activity. A number of patterns of map reorganization have been described after stroke; for the upper extremity motor represen-
tational map, a posterior or a ventral shift has been described most often. In (D), Weiller et al. (1993), using a PET measure of regional
cerebral blood ﬂow, demonstrated that in patients with capsular infarct such as the case depicted, motor cortex activity extended from the
hand area (arrowhead) ventrally into the face area (arrow). (E–G) Brain plasticity associated with treatment-induced recovery. A number of
training paradigms have been introduced to patients in the chronic, plateau phase of stroke. Behavioural gains in the affected arm in this
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(continued)may reﬂect both adaptive and maladaptive neuroplasticity, which
can occur simultaneously.
Neuropsychiatric disorders
Brain plasticity in the setting of neuropsychiatric disorders shows
some similarities with that found in the setting of CNS injury such
as stroke, but also shows a number of important differences. In
both settings, plasticity has been described as part of the adapta-
tion to pathology. However, the nature of the CNS pathology in
neuropsychiatric disorders results in additional forms of altered
brain structure and function. Mental and addictive disorders do
not result from speciﬁc localizable lesions in the nervous system,
in contrast to the relatively well-deﬁned lesions that occur in
stroke and trauma. Instead, these disorders are characterized by
abnormalities in the distributed limbic, prefrontal and frontostriatal
neural circuits that underlie motivation, perception, cognition, be-
haviour, social interactions and regulation of emotion (Beauregard
et al., 2001). Also in contrast to stroke and trauma, the onset of
mental and addictive disorders is usually insidious; the course of
illness tends to be chronic or recurring/episodic; recovery in most
of these disorders is slow when present; and relapse rates are high,
with each episode of illness increasing the likelihood of future
episodes (Patten, 2008; Robinson and Berridge, 2008).
Expression of these illnesses drives change in key neural systems
in the direction of ever more dysfunctional patterns underlying
thoughts, emotions and complex behaviours. An important
point, therefore, is that CNS plasticity, while a mechanism for
achieving therapeutic gains in neuropsychiatric disorders (below)
as in other settings, also has a large inﬂuence on disease patho-
genesis in these disorders (Sullivan and Pfefferbaum, 2005).
Mental and addictive disorders are known to have a strong
neurodevelopmental component and are associated with polygenic
risk factors. However, their clinical trajectories are also experience
dependent, and so heavily inﬂuenced by environmental and ex-
periential phenomena such as stress, exposure to substance use,
psychological trauma, social attachments, internal representations
of self and other sociocultural inﬂuences such as the degree of
early stress and of nurturing (Grossman et al., 2003; Leonardo
and Hen, 2008). Prefrontal cortical association areas are particu-
larly noteworthy in relation to clinical expression of neuropsychi-
atric disorders. These areas play a role in many of these
environmental and experiential phenomena, as well as in social
cognition, cognitive appraisal and impulse control, and are highly
plastic (Lewis, 2009; Goto et al., 2010), late to myelinate
(Yakovlev and Lecours, 1967) and modiﬁable by individual cogni-
tive and affective experiences. Recent evidence provides further
support for this at the cellular level, with prefrontal cortical neu-
rons demonstrating synaptic plasticity and showing lasting changes
in neural activity associated with divergent cognitive processes
(Goto et al., 2010).
Because it is difﬁcult to establish valid animal models for most
human psychiatric illnesses, evidence for the speciﬁc role that plas-
ticity mechanisms play in disease expression remains speculative,
although compelling in a number of cases. For example, animal
studies show that long-term potentiation of hippocampal–pre-
frontal synapses is driven by levels of mesocortical dopaminergic
activity, with acute stress serving as an environmental determinant
of long-term potentiation at these cortical synapses (Jay et al.,
2004). The ‘kindling model’ suggests that heightened neural sen-
sitivity to speciﬁc triggers reﬂects plasticity in N-methyl-D-aspartate
receptor functioning in addiction (Post and Weiss, 1996) and in
other neuropsychiatric disorders (Grossman et al., 2003). Also,
putative schizophrenia risk genes such as those related to
DISC-1, dysbindin, brain-derived neurotrophic factor and the N-
methyl-D-aspartate receptor, are involved in regulating neuroplas-
ticity, and it is possible that alterations in their expression may
contribute to the abnormal patterns of cortical connectivity
observed in schizophrenia (Balu and Coyle, 2011). Disturbances
in dorsolateral prefrontal cortex circuitry are especially prominent
in schizophrenia and may reﬂect direct pathology, as well as de-
velopmental plastic changes secondary to underlying disease else-
where in the brain (Lewis and Gonzalez-Burgos, 2008). Plasticity
in neuropsychiatric disease can also arise as a consequence of
therapy, as in the maladaptive plasticity occurring in the form of
tardive dyskinesia, associated with many antipsychotic medica-
tions, particularly ﬁrst-generation drugs.
A noteworthy exception regarding the paucity of valid animal
models in psychiatry is found in the addictive disorders, where a
rich array of models is available for study (Shaham et al., 2003;
Guo et al., 2006; Ninkovic and Bally-Cuif, 2006). An emerging
synthesis from such studies is that drug abuse represents a rigid
and stereotyped behavioural repertoire driven by maladaptive
plasticity in subcortical reward circuitry, one that is highly resistant
to reversal, making it difﬁcult to establish new behaviours to
Figure 2 Continued
context are in general associated with an increase in the volume of activity and excitability of motor cortex, as well as an increase in
laterality, back towards normal, i.e. with a greater predominance of activity in stroke-affected motor cortex rather than bilateral activation.
In (E), Takahashi et al. (2008), using serial functional MRI scans across 3 weeks of robot-based physiotherapy in patients with stroke
affecting the left brain, found that therapy centred around right (paretic) hand grasping movements was associated with a 420-fold
increase in left (stroke-affected) sensorimotor cortex (arrow); some speciﬁcity of treatment effect was apparent given absence of
signiﬁcant change in the map for supination, a similar but non-rehearsed task. Similar results have been described across treatment
modalities. (F) Tardy et al. (2006) found that the stimulant methylphenidate improved motor performance in the paretic hand, which was
paralleled by increased functional MRI activation in sites that included stroke-affected primary sensorimotor cortex (arrow). Laterality also
changes with treatment. (G) Carey et al. (2002), using functional MRI, found that training of the paretic ﬁnger was associated with an
increase in the primary sensorimotor cortex laterality index during performance of the trained movement. The laterality index varies from
+1 (all sensorimotor cortex activation is contralateral to movement) to –1 (all activation is ipsilateral to movement). Prior to therapy, the
value for stroke patients was –0.26. After therapy, the value increased to +0.43, reﬂecting a shift of activation towards the stroke-
affected hemisphere during paretic ﬁnger movement, and matching more closely the values observed in treated healthy control subjects.
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2010). Disruption of prefrontal regulation of subcortical limbic
neural circuitry (Robinson and Kolb, 2004; Goto and Grace,
2008) and frontostriatal neural circuitry (Koob and LeMoal,
2006) is seen. Prefrontal control mechanisms are thus hijacked
by subcortical reward systems in order to support the drug-seeking
behaviour, with a loss of adaptive ﬂexibility; free of inhibitory
modulation imposed by prefrontal cortex, drug abuse comes
under the control of evolutionarily older regions that execute
ﬁxed responses to environmental stimuli. These circuit level shifts
may be explained by neuroplastic changes at the cellular level,
such as loss of glutamate homoeostasis in the nucleus accumbens
and loss of synaptic plasticity in striatal spiny neurons, which affect
the tone of perisynaptic metabotropic glutamate receptors that are
critical for long-term potentiation (Kalivas et al., 2009) and
long-term depression (Kalivas et al., 2009).
At least some aspects of treatment-induced behavioural im-
provement in psychiatric and addictive illnesses are accompanied
by plastic changes in the brain. For example, 2 years of social skills
group therapy plus cognitive remediation for early schizophrenia is
accompanied by signiﬁcant grey matter increases in left hippocam-
pus and left amygdala, the extent of which correlate with the
degree of improved cognition (Eack et al., 2010). Deep brain
stimulation that disrupts focal pathological activity in
limbic-cortical circuits can reverse symptoms of treatment-resistant
depression, and these antidepressant effects are associated with
plasticity in downstream limbic and cortical sites (Mayberg et al.,
2005). Sustained alcohol abstinence results in improvements in
frontal white matter integrity (Gazdzinski et al., 2010). At the
cellular level, increased hippocampal neurogenesis, potentially re-
ﬂective of reparative events and thus plasticity, has been demon-
strated in animal models with antidepressant medications,
electroconvulsive therapy and stress reduction techniques such as
environmental enrichment and exercises (Sahay and Hen, 2007).
These initial ﬁndings suggest that successful treatment of mental
disorders induces meaningful plasticity at the cellular level, as well
as in the structure and function of frontal–subcortical neural
systems.
Paediatric and developmental disorders
Paediatric congenital and acquired disorders superimpose injury on
a developing nervous system that has a unique capacity for certain
forms of plasticity. Injury to the developing brain can modify syn-
aptic mechanisms, change neuronal activity, interfere with normal
development and plasticity, or alter the range of activities and
experiences to which a child is exposed during development.
The timing of an insult, particularly with respect to age (Gardner
et al., 1955; Chen et al., 2002b; Staudt, 2010) or to developmen-
tal critical periods (Cohen et al., 1999; Eyre, 2007; Jacobs et al.,
2007; Johnston et al., 2009; Sharma et al., 2009a) can strongly
inﬂuence the ultimate impact on plasticity and function. Many
forms of neuroplasticity are at their maximum during early devel-
opmental stages that are exclusive to the developing brain. For
example, cross-modal plasticity, deﬁned as the ability of sensory
maps to reorganize across afferent modalities when normal input
is deprived, has been described in humans who have sustained an
early neural insult (Pascual-Leone and Torres, 1993). Shifts in
function from one side of the brain to the other can occur at a
grand scale, with much more favourable behavioural effects in
children than in adults. After large injury to a dominant left hemi-
sphere, the right hemisphere often shows moderate to good con-
trol of language or right body movements in a child with very
early insult (Staudt et al., 2002; de Bode et al., 2005), but poor
control in an adult with stroke. Note too that early brain injury can
impair subsequent plasticity (Failor et al., 2010).
Several hypotheses concerning the interaction of development
with neuroplasticity have emerged. For example, a greater pro-
pensity for large-scale neuroplasticity in the paediatric age range
(Kennard, 1942) has been hypothesized to be attributable to the
overabundance of neuronal cells and synaptic connections that
characterize early postnatal development, which then undergo
pruning through a discrete period of experience-dependent com-
petition. Other developmental events, such as maturation of in-
hibition, extracellular matrix and myelination, might also account
for the closure of developmental critical periods with their unique
forms of plasticity. Many of these hypotheses require further
study.
Plasticity during development can also be adaptive or maladap-
tive. Two cardinal examples of adaptive plasticity in relation to
development are the age-dependent recovery of language and
motor functions following hemispherectomy for intractable epi-
lepsy and the ability to beneﬁt from a cochlear implant in early
childhood. After hemispherectomy, the shift of language and
motor functions to the non-removed hemisphere is remarkable,
but highly dependent on age, with the greatest potential for re-
organization seen in children under 6 years of age (Gardner et al.,
1955; Chen et al., 2002b); interpretation of such plasticity meas-
ures must bear in mind that they arise in the setting of an atypical
brain at baseline. Congenitally deaf children appear to beneﬁt
most from cochlear implants within the ﬁrst 3.5 years of life, a
time during which the central auditory pathways show maximal
plasticity. Recent research shows that the latency of the early (P1)
component of the cortical auditory evoked potential falls within
the normal range for age among children who receive an implant
by 3.5 years of age. In contrast, those who receive implants after
7 years of age show abnormal cortical responses even years after
receiving the implant (Sharma et al., 2002, 2009a).
Maladaptive plasticity has been described in the setting of early
sensory deprivation, which often results in an aberrant neural or-
ganization. Within the auditory system, the lack of typical experi-
ence imposed by deafness results in a failure of proper
development of projections from secondary back to primary audi-
tory areas, which weakens important feedback loops (Sharma
et al., 2009a). It is likely that this decoupling makes secondary
areas more available to other modalities (Kral et al., 2006). In the
visual system, congenital cataracts or other optical problems that
limit visual input disadvantage corresponding sensory ﬁbres in their
competition for space in the visual cortex, resulting in permanent
visual deﬁcits such as amblyopia (Awaya, 1987).
Early-onset diseases of the nervous system often affect speciﬁc
cell types or neurotransmitter systems, which are reiterated across
multiple brain regions and functional domains, and which are
important modulators of neuroplasticity. For example, Down
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tion, several motor disorders involve alterations of dopaminergic
circuitry, and epilepsy may involve deﬁcits in GABAergic function.
Likewise, hormonal (e.g. thyroid disease) and metabolic (e.g.
phenylketonuria) disorders can have diffuse effects on the de-
veloping brain. Fortunately, some of these effects can be pre-
vented with early detection and treatment. One of the most
surprising ﬁndings of recent years comes from animal studies
that suggest that many genetic developmental defects, including
those that affect neural plasticity, can largely or completely be
reversed in adult life by reversing the biochemical defect
(Ehninger et al., 2008); such ﬁndings indicate that therapy may
be effective in cases where it had been thought not to be so.
Neurodegeneration and ageing
Neuroplastic changes in neurodegeneration and ageing have been
described, may represent pathogenic or compensatory responses,
and are likely of functional consequences, at least in their earlier
stages (Prvulovic et al., 2005; Palop et al., 2006; O’Brien et al.,
2009). Generally speaking, neurodegenerative diseases are char-
acterized by progressive declines in behavioural and neural func-
tion, often manifest through a pathogenic process in a
maladaptive cycle. Important new research reveals that patho-
logical molecules can directly inﬂuence neuroplasticity at the syn-
aptic level. For example, amyloid-beta dimers, when puriﬁed from
post-mortem tissue from patients with Alzheimer’s disease and
injected into rodents, can affect synaptic plasticity, thus establish-
ing a possible cellular mechanism for pathology-induced plasticity
in brain circuits (Shankar et al., 2008). While data derived from
animal studies and human post-mortem tissue support an inverse
correlation between synaptic plasticity and pathological burden
(DeKosky et al., 1996), thereby suggesting that decreased plasti-
city may further exacerbate pathology, the direct effects of these
processes in living patients have yet to be demonstrated.
Another perspective on neuroplasticity with degenerative dis-
eases is that, with increasing pathology over time, compensatory
mechanisms may fail or perhaps even become pathogenic via their
effects on vulnerable neuronal populations, thereby destabilizing
networks (Palop et al., 2006). Neurophysiological evidence of
increased association cortex responsiveness in the early stages of
Alzheimer’s disease might reﬂect dynamic compensation for the
impaired transmission of signals from primary cortex processing
centres (Fernandez et al., 2007). However, over time, such com-
pensatory activity might have detrimental consequences, possibly
mediated by excitotoxic mechanisms. Similar ideas have been
advanced in other neurodegenerative conditions; for example, in
Huntington’s disease, the high frequency of synaptic activation
required to maintain medium-sized spiny neurons in an excitable
state might render these cells more susceptible to cellular stress
(Milnerwood and Raymond, 2010). Clariﬁcation of whether
changes in neural activity are compensatory or pathogenic may
hold implications for treatment, as some network dysfunctions
may be reversible. Normalization of network activity might help
prevent progressive neuronal loss (Palop et al., 2006).
Changes associated with neurodegenerative diseases can be
superimposed on declines and reduced plasticity associated with
normal ageing (Gould et al., 2006; Mahncke et al., 2006; Hertzog
et al., 2009). Such age-related changes include reductions in pro-
cessing speed, working memory and peripheral nervous system
functions, which may be associated with changes in brain
volume, white matter integrity, regional brain activation patterns
and cellular function (Park and Reuter-Lorenz, 2009). Indeed,
ageing may alter the genetic control of key plastic events, such
as axonal sprouting after injury (Li et al., 2010). A traditional view
is that ageing-related declines are a direct consequence of adverse
changes in brain structure and function. An alternative view holds
that such declines result, in part, from reduced engagement in
cognitively demanding and stimulating tasks, degraded sensory
input and/or weakened neuromodulatory control (Mahncke
et al., 2006; Hertzog et al., 2009), thus opening possibilities for
preventive interventions targeted towards driving brain plasticity.
As people with prior neurological impairment from stroke or cere-
bral palsy age, their experience- and activity-induced plasticity that
led to improved daily functioning may decline due to modest deg-
radation in networks that retain less reserve than in those of
healthy people.
The capacity of cognitive reserve may underlie the differential
effects of neuroplasticity in ageing and the vulnerability to the
detrimental effects of neurodegenerative diseases (La Rue,
2010). For instance, the common observation that the same
burden of Alzheimer pathology may not impair patients’ cognitive
functions to the same extent is often taken as evidence of greater
cognitive reserve in less impaired individuals. The effects of path-
ology may be clinically silent inasmuch as they are associated with
the maintenance of a stable behavioural phenotype. Such adaptive
plasticity might play a useful role in compensation for ageing ef-
fects (Cabeza et al., 2002; Park and Reuter-Lorenz, 2009) and
may also be amenable to facilitatory interventions involving
drugs (Floel et al., 2008) or non-invasive brain stimulation
(Hummel et al., 2010). Moreover, recent animal studies demon-
strate the profound effects that environmental enrichment can
have on brain function, possibly inducing adaptive neuroplasticity
and reducing key histopathological markers of neurodegeneration
(Lazarov et al., 2005). However, it remains to be determined
whether these strategies can be translated into treatments target-
ing the functional declines seen in neurodegenerative diseases.
Selected examples of
neuroplasticity-based interventions
A number of promising interventions targeted towards promoting
neuroplasticity are highlighted below. The examples are meant to
be illustrative, rather than exhaustive. In many cases, these inter-
ventions represent application of neuroscience knowledge to re-
habilitation techniques. Examples include appreciation of learning
theory, Hebbian principles, task-speciﬁc training, social inﬂuences,
mechanisms of verbal encoding and the interplay across brain
modalities (such as inﬂuence of deafferentation on motor func-
tion). Such interventions are increasingly being applied mindful
of overarching principles of neuroplasticity (Kleim and Jones,
2008). For example, plasticity after injury is often experience de-
pendent. Thus, interventions that aim to promote plasticity can be
expected to have maximum impact when coupled with optimal
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experiences on behavioural outcomes might require use of
domain-speciﬁc measures (Cramer et al., 2007a). For example,
recovery of language in a patient with post-stroke aphasia is inﬂu-
enced by optimal language therapy (Bhogal et al., 2003); this
language recovery is better detected with a scale that is sensitive
to the language domain as compared with a global scale of overall
status. Also, plasticity can be time-sensitive, occur with consider-
able speciﬁcity, vary with the nature of the environment and be
strongly inﬂuenced by the extent of concomitant training.
Salience, motivation and attention can be critical modulators of
plasticity (Woldag and Hummelsheim, 2002; Nithianantharajah
and Hannan, 2006; Kleim and Jones, 2008). Skills training illus-
trates a direct example of harnessing neuroplasticity to achieve
clinical gains; training on selected skills has been found to improve
behavioural outcomes in parallel with increased brain plasticity, in
the setting of numerous forms of CNS disease. The extent to
which outcomes can be improved on the backbone of such train-
ing and plasticity depends on availability of sufﬁcient residual
neural resources, regardless of the type or duration of the neuro-
logical insult (Riley et al., 2011). A major challenge, as discussed
below, is to match the right patients with the right training
approach.
The pursuit of neuroplasticity-based interventions beneﬁts from
strong collaborations between basic and clinical researchers
(Hachinski et al., 2010), from preclinical investigations to clinical
trials. For example, clinical scientists can better understand the
limitations and assumptions in the animal models; basic research-
ers, in turn, can return to the lab to ask pivotal questions upon
informed review of early phase human studies. Such an approach
stands to provide the best understanding of plasticity mechanisms,
from genes to molecules to cells to networks to behaviour.
Non-invasive brain stimulation
Several forms of non-invasive brain stimulation have been exam-
ined as a means to change brain function and thereby promote
neuroplasticity (Webster et al., 2006; Plow et al., 2009). Chief
among these is transcranial magnetic stimulation. Introduced in
the mid-1980s, transcranial magnetic stimulation uses an extracra-
nial magnetic coil to induce current in the cerebral cortex (Wagner
et al., 2007). Although transcranial magnetic stimulation activates
a mixed population of inhibitory and excitatory cortical inter-
neurons, in general, continuous trains of low frequency (51Hz)
repetitive transcranial magnetic stimulation or theta burst transcra-
nial magnetic stimulation lead to suppression of cortical excitability
in healthy subjects, while intermittent, bursting high frequency
(41Hz) trains of repetitive transcranial magnetic stimulation or
intermittent theta burst transcranial magnetic stimulation lead to
facilitation (Wagner et al., 2007). Transcranial magnetic stimula-
tion can be applied speciﬁcally and selectively to deﬁned cortical
regions, particularly when guided by neuroimaging and physio-
logical measures (Neggers et al., 2004; Kleim et al., 2007).
Transcranial direct current stimulation uses two scalp electrodes
to induce low-amplitude direct currents strong enough to pene-
trate the brain and modify membrane potentials, thereby inﬂuen-
cing neuronal excitability, but without triggering the depolarization
of neurons (Wagner et al., 2007). Both techniques can produce
effects that are ‘ofﬂine’, i.e. that endure beyond the period of
stimulation (Fregni and Pascual-Leone, 2007; Reis et al., 2009).
The optimal stimulation paradigms and the best means of behav-
ioural reinforcement require further study.
Several strategies build on the basic capacity of stimulation to
modulate brain activity. Combination therapies, such as adding
concomitant pharmacological or peripheral nerve stimulation,
have the potential to further drive Hebbian plasticity (Conforto
et al., 2010) and are under study. Also, combination with imagery
or behavioural intervention has the potential to increase the efﬁ-
cacy of neuromodulation (Edwards et al., 2009). Another set of
approaches builds on the model that, following stroke, cortical
excitability is decreased in the ipsilesional hemisphere as a result
of increased transcallosal inhibition from the contralesional hemi-
sphere and increased in the contralesional hemisphere (Murase
et al., 2004; Nowak et al., 2009). Building on this model, enhan-
cing excitability of the affected hemisphere using high-frequency
repetitive transcranial magnetic stimulation or suppressing the con-
tralesional hemisphere via low-frequency repetitive transcranial
magnetic stimulation or cathodal transcranial direct current stimu-
lation appears in initial studies to promote gains in motor function,
at least among patients with mild to moderate impairment (Fregni
and Pascual-Leone, 2007). Promising initial results have also been
reported with this approach in the treatment of other neurological
domains, such as aphasia (Martin et al., 2004).
The ability of repetitive transcranial magnetic stimulation to
induce electrical stimulation in cortex and the hypothesis that it
might produce anti-depressant effects similar to electroconvulsive
therapy has resulted in several studies on its efﬁcacy for depres-
sion. Daily prefrontal transcranial magnetic stimulation for several
weeks has been shown to have signiﬁcant antidepressant effects,
but additional work is needed to optimize protocols and establish
and improve effect sizes (O’Reardon et al., 2007; Padberg and
George, 2009). Importantly, repetitive transcranial magnetic
stimulation effects have been shown to spread to distal anatom-
ically connected structures across speciﬁc networks, including
deeper striatal and limbic structures (Speer et al., 2009). Thus,
cortical stimulation might induce plastic changes in cortex directly
or indirectly by modifying activity in basal ganglia networks. A key
principle in neuroplasticity is the value of coupling a
plasticity-promoting intervention with behavioural reinforcement;
further efforts in this regard might maximize the impact of repeti-
tive transcranial magnetic stimulation on depression.
The ability of repetitive transcranial magnetic stimulation to
induce changes in cortical function has also been examined in
schizophrenia. The left temporoparietal cortex is one of several
regions whose overactivity is associated with the perception of
external voices in hallucinating patients. Low-frequency stimula-
tion of temporoparietal cortex has been used experimentally to
inhibit cortical excitability and thereby quell severe,
treatment-resistant auditory hallucinations with some success
(Hoffman et al., 2007; Stanford et al., 2008; Bagati et al.,
2009; Vercammen et al., 2009). However, these studies are char-
acterized by small sample sizes and some methodological incon-
sistencies, making it difﬁcult—at this point in time—to compare
study ﬁndings and draw deﬁnitive conclusions about the precise
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Deep brain stimulation
Like transcranial magnetic stimulation, deep brain stimulation uses
electrical stimulation to induce neuroplasticity and produce behav-
ioural changes, although with deep brain stimulation, electrical
current is provided through implanted electrodes. Stimulation par-
ameters such as frequency, intensity and pulse width are program-
mable and can be optimized (Denys and Mantione, 2009). Two
generally hypothesized mechanisms of action are that deep brain
stimulation creates a functional lesion via inhibition within the
stimulated region and, alternatively, that deep brain stimulation
activates the neuronal network connected to the stimulated
region, leading to modulation of pathological network activity
(Johnson et al., 2008). The former mechanism is more consistent
with the immediate effects of some applications of deep brain
stimulation (e.g. effects on motor function in Parkinson’s disease),
while the latter may be more consistent with deep brain
stimulation-induced gradual effects (e.g. circuit retraining) as
seen in neuropsychiatric disorders.
Following increased use of deep brain stimulation in Parkinson’s
disease and reports of its effects on emotion, interest in its appli-
cation to severe, treatment-resistant mental disorders has grown.
A challenge in using deep brain stimulation for disorders of mood,
thought and behaviour is the identiﬁcation of appropriate and
optimal stimulation sites. Although a primate model
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, also known as
MPTP) has been useful for deﬁning a stimulation site in
Parkinson’s disorder, animal models have generally been of limited
value in psychiatry. Human neuroimaging and prior lesioning stu-
dies have thus been very useful in identifying putative deep brain
stimulation targets that may be appropriate for treating psychiatric
disorders (Greenberg et al., 2010b). In mood and anxiety dis-
orders, human neuroimaging studies have generally highlighted
prefrontal cortex, subcallosal cingulate cortex (Brodmann area
25), hippocampus and amygdala as dysregulated. Preliminary stu-
dies of deep brain stimulation targeting the subcallosal cortex
(Brodmann area 25) and its adjacent white matter tracts have
shown promise in treating depression, suggesting that disruption
of the pathological limbic-cortical circuit may ameliorate
treatment-resistant depression (Mayberg et al., 2005; Lozano
et al., 2008). Similar response rates have also been shown with
stimulation of both the nucleus accumbens and anterior limb of
the internal capsule (Malone et al., 2009; Bewernick et al., 2010),
ﬁndings that also require further study.
Deep brain stimulation is also showing promise as a potential
treatment for refractory obsessive-compulsive disorder, thought to
involve overactivity of cortico-striatal-limbic circuits. Deep brain
stimulation produced substantial behavioural improvements in at
least half of the 60 subjects with obsessive–compulsive disorder
studied over 10 years (Denys and Mantione, 2009). The most
common target in obsessive–compulsive disorder has been the in-
ternal capsule (Greenberg et al., 2010a) extending into the ventral
striatum, based on positive experiences with gamma capsulotomy
and functional neuroimaging ﬁndings. Use in the related
Tourette’s syndrome is more limited, but has targeted the medial
thalamus and the globus pallidus internus, the latter based on
studies in hyperkinetic states such as dystonia and dyskinesias of
Parkinson’s disease (Larson, 2008).
As with many forms of plasticity, behavioural gains depend on
continued therapeutic exposure. Thus, while improvement in de-
pression and obsessive-compulsive disorder symptoms are progres-
sive over months of chronic deep brain stimulation, they worsen
progressively with termination of stimulation, although some
metabolic changes linger after chronic deep brain stimulation
(Lujan et al., 2008). This supports the contention that deep
brain stimulation can induce some long-term neuroplastic changes
in neuropsychiatric disorders. Whether durable changes that sur-
vive ongoing stimulation are possible remains to be established.
Other forms of invasive brain stimulation are under study.
Activity-dependent stimulation is a promising new modality for
inducing plasticity. An electronic circuit that used neural activity
recorded at one cortical site to trigger stimuli delivered at another
site in freely behaving primates produced long-term changes in
neural connections (Jackson et al., 2006). The conditioning effects
depended on the delay between the recorded action potentials
and the stimuli, indicating a spike-timing dependent Hebbian plas-
ticity. Negative ﬁndings have been described in a phase III trial of
a different form of stimulation, epidural. Epidural motor cortex
stimulation combined with physiotherapy was not found to be
superior to physiotherapy alone for improvement of upper extrem-
ity motor deﬁcits in patients with chronic stroke (Levy et al.,
2008).
Neuropharmacology
The cellular and molecular events that underlie neuroplasticity
occur on the backbone of speciﬁc neurochemical processes that
are accessible and vulnerable to pharmacological interventions
(Floel and Cohen, 2010). Pharmacotherapies can increase neuro-
plasticity through molecular manipulation of numerous cellular and
synaptic pathways, such as HDAC inhibitors, mTOR inhibitors and
trkB agonists (Vecsey et al., 2007; Potter et al., 2010). They
appear to be especially promising when used to augment
circuit-speciﬁc training, i.e. to enhance experience-dependent neu-
roplasticity. One clear example is the ability of D-cycloserine to
signiﬁcantly augment the effects of exposure/extinction therapy
for anxiety disorders by facilitating the activation of N-methyl-D-
aspartate glutamate receptors (Ressler et al., 2004). The systems
and behavioural level responses to treatments that promote neu-
roplasticity have been well reviewed elsewhere (Buonomano and
Merzenich, 1998; Strangman et al., 2005; Hodics et al., 2006;
Penner et al., 2006; Frewen et al., 2008; Rosser and Floel,
2008; Swart et al., 2009). A number of studies have provided
mechanistic insights into these pharmacological effects. For ex-
ample, Pariente et al. (2001), using functional MRI, found that
administration of ﬂuoxetine to patients with stroke improved
motor function in parallel with increased activation in the ipsile-
sional motor cortex.
Many of the above principles of plasticity extend to pharmaco-
logical approaches. For example, pharmacological targets can vary
over time, and plasticity can change with experience and environ-
ment (Woldag and Hummelsheim, 2002; Nithianantharajah and
Hannan, 2006; Kleim and Jones, 2008). In some cases, a drug
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with speciﬁc activities, such as with animal models of motor
deﬁcits after CNS injury (Feeney et al., 1982; Garcia-Alias et al.,
2009), or with combined use of medication and cognitive-
behavioural psychotherapy in the treatment of human depression
(DeRubeis et al., 2008). It is important to note that the molecular
mechanisms that support plasticity also have pharmacological vul-
nerabilities. Behavioural gains induced by plasticity-promoting
pharmacological interventions can be lost, for example, with
N-methyl-D-aspartate blockade or increased GABAergic tone.
Indeed, many classes of drugs can retard neuroplasticity (Feeney
et al., 1982; Buteﬁsch et al., 2000) and possibly reduce behav-
ioural gains (Goldstein and Sygen in Acute Stroke Study
Investigators, 1995; Lazar et al., 2003).
Physical training and exercise
Following injury to the brain or spinal cord that induces motor
deﬁcits, many physical rehabilitation interventions have been re-
ported to induce functional improvements. Constraint-induced
movement therapy for the arm and hand (Wolf et al., 2007),
body weight-supported treadmill training (Dobkin et al., 2006;
Duncan et al., 2007), robotic devices (Volpe et al., 2008; Hidler
et al., 2009; Housman et al., 2009; Lo et al., 2010), behavioural
shaping, bilateral arm training (Lin et al., 2010) and task-oriented
physical therapy (Jonsdottir et al., 2010) are all examples of inter-
ventions that have led to improved recovery following stroke. In
some cases, functional neuroimaging studies have provided in-
sights into mechanisms of treatment effects; for example,
constraint-induced movement therapy of the upper extremity
has been associated with an enlarged motor cortex map for the
hand (Sawaki et al., 2008) as well as with bilateral increases in
sensorimotor grey matter (Gauthier et al., 2008). However, the
more complex training interventions, such as the use or robotic
devices and treadmill locomotor training, generally have not im-
proved outcomes more than conventional task related and
strengthening therapies that also aim to optimize activity-
dependent plasticity. Likewise, among patients with incomplete
spinal cord injury, training through robotic-assisted and body
weight-supported techniques have improved walking only to a
similar degree as standard over-ground training (Dobkin, 2007).
Further research is needed to better understand how these thera-
pies can be coordinated and optimized, especially across diverse
patient groups with varied functional limitations. Practice strategies
include increased repetition, sensory priming, visualization, modu-
lation of attentional valence and reward, contextual interference,
variable demand and intensity levels, blocked versus intermittent
practice and various forms of feedback (Kwakkel et al., 1999;
Subramanian et al., 2010). Although these practice paradigms
may enhance both skills and declarative learning in healthy sub-
jects, their additive beneﬁts for patients with impaired movement
or cognition has been difﬁcult to demonstrate. Note that physical
rehabilitation training is not only a stand-alone therapy, but serves
as an adjunct to other forms of therapy such as pharmacological
and behavioural.
Aerobic exercise is a speciﬁc extension of activity-based thera-
pies for promoting plasticity. Although the beneﬁts of aerobic ex-
ercise in preventing or reversing cognitive and neural deterioration
have yet to be fully investigated, substantial human and preclinical
data support the utility of such exercise for promoting brain plas-
ticity and improving CNS function in many conditions (Cotman
and Berchtold, 2002; Hillman et al., 2008), including normal
ageing and early dementia. Aerobic exercise is associated with
increased neurogenesis and angiogenesis, as well as the produc-
tion of neurotrophic molecules such as brain-derived neurotrophic
factor and other growth factors involved in neuroprotection and
the promotion of cell survival, neurite outgrowth and synaptic
plasticity (Cotman and Berchtold, 2002; Gomez-Pinilla et al.,
2002; Farmer et al., 2004; Kramer and Erickson, 2007; Rhyu
et al., 2010). In humans, neuroimaging studies have described a
range of anatomic and functional correlates of such effects
(Dustman et al., 1990; Colcombe et al., 2003; Pereira et al.,
2007; Pontifex et al., 2009; Pajonk et al., 2010). Furthermore,
these plasticity-promoting strategies are able to produce clinically
signiﬁcant changes. For example, aerobic exercise programmes
lasting even just a few months signiﬁcantly beneﬁt cognitive func-
tioning in both healthy ageing and early dementia, may be of
beneﬁt in schizophrenia (Colcombe et al., 2004; Kramer and
Erickson, 2007), and have been shown to increase brain volume
in a variety of regions (Colcombe et al., 2006; Pajonk et al., 2010)
and to enhance brain network functioning (Colcombe et al.,
2004).
Cognitive training
Cognitive training can be thought of as a direct extension of phys-
ical therapy to the non-motor aspects of the human brain and so
has been examined across a number of disease conditions.
However, the complexities of the distributed neural systems that
underlie human behavioural syndromes introduce unique chal-
lenges for the design of effective interventions. In depression
and anxiety disorders, a long tradition of evidence-based
cognitive-behaviour therapy is based on the principle of identifying
and modifying top-down responses to maladaptive cognition,
affect and behaviour (Beck, 2005; Walkup et al., 2008).
Evidence suggests that, as individuals learn to modify their cogni-
tive representations and behavioural responses to distressing sti-
muli, widespread changes occur in frontal cognitive control
systems and in limbic system activation (Goldapple et al., 2004;
Kennedy et al., 2007; Farb et al., 2010).
New neuroscience-driven approaches to cognitive training are
emerging and directly build on decades of animal research that
have identiﬁed principles of harnessing plasticity mechanisms in
the adult brain (Nudo et al., 1996; Buonomano and Merzenich,
1998). For example, the cognitive deﬁcits of schizophrenia—par-
ticularly in verbal learning and memory—are associated with illness
severity and predict long-term functioning, but do not respond to
currently available medications. Vinogradov et al. (2008), guided
by an understanding of the neurobiology of schizophrenia, per-
formed a double-blind randomized controlled trial of intensive
computerized cognitive training exercises that focus on the com-
ponents of auditory and verbal processing that underlie verbal
encoding. This intervention was associated with improved verbal
memory in patients, as well as magnetoencephalographic evidence
of increased amplitude of the M100 response to auditory
stimuli, indicating plasticity in auditory cortex (Dale et al., 2010).
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multi-site, study. Another cognitive-based, neuroscience-driven
training approach aims to stimulate speciﬁc dysfunctional circuits,
possibly in association with pharmacological intervention, in order
to restore the integrity of frontostriatal circuitry in addiction
(Packard, 2009).
Neuroimaging can contribute to cognitive training in a number
of ways. Functional brain imaging can help to identify the neural
correlates of various core mental processes such as interference
control that can be targeted by cognitive training and that are
relevant for a number of psychiatric disorders (Dahlin et al.,
2008; Persson and Reuter-Lorenz, 2008). Neuroimaging data
can also be used as biomarkers, i.e. surrogate markers. A surrogate
marker has been deﬁned as ‘a laboratory measurement...used as
a substitute for a clinically meaningful endpoint’ (Temple, 1995).
For example, changes in functional MRI brain activation have been
shown to correlate with functional gains in studies that employed
cognitive training in the setting of schizophrenia (Farb et al., 2010;
Haut et al., 2010), dyslexia (Temple et al., 2003) and depression
(Farb et al., 2010), consistent with observations in studies that
employed direct instructional approaches (Aylward et al., 2003;
Eden et al., 2004; Keller and Just, 2009). Such imaging biomarkers
might prove useful as predictors of clinical outcome, and a number
of MRI and PET measures are under study in this regard
(Rosenberg and Hillis, 2009). Neuroimaging can also provide mo-
lecular insights into treatment mechanism. For example, McNab
et al. (2009) found that cognitive training in healthy subjects was
associated with changes in the density of cortical dopamine D1
receptors on PET scanning, a ﬁnding relevant to the treatment of
children with attention deﬁcit disorder (Klingberg et al., 2005).
PET has also been used to describe changes in glucose metabolism
associated with cognitive-behavioural or pharmacological treat-
ment of depression (Goldapple et al., 2004; Kennedy et al.,
2007). Though promising on a number of fronts, a number of
issues remain to be addressed to maximize the impact of neuro-
imaging on cognitive training. Most imaging work has been per-
formed on small samples, with differing approaches across labs,
such as in relation to the underlying hypotheses of mechanisms of
training-induced change, and further study is needed regarding
the validity and reliability of neuroimaging data. Critically import-
ant is the question of whether changes in circuit strength demon-
strated using neuroimaging are paralleled by meaningful
behavioural changes.
The ultimate goal of cognitive training is to improve behaviour
by systematically harnessing neuroplasticity and driving adaptive
changes in dysfunctional neural systems through carefully de-
signed exercises. Note that cognitive training approaches have
particularly broad potential, for example, as part of rehabilitation
therapy of patients with focal brain injury such as stroke, where
myriad cognitive syndromes exist with few treatment options, as
well as in the treatment of numerous neuropsychiatric disorders
such as depression and schizophrenia. Systems neuroscience-
informed cognitive training appears to be a promising treatment
approach for a number of brain disorders. A key future direction
for this ﬁeld will be to maximize the extent to which cognitive
training in one domain generalizes to others, and the extent to
which such training has a meaningful impact on real-world
functioning as well as the subjective experience of the individual
(Green and Bavelier, 2008).
Feedback using real-time functional magnetic
resonance imaging
A central challenge to creating neuroplastic change is determining
how to target plasticity to a particular brain system. Such targeting
might be enabled by the ability to monitor changes in brain acti-
vation within localized brain regions in real time. Recent advances
in neuroimaging and computing have enabled the development of
such methods based on functional MRI-based measures of region-
al brain activation (Cox et al., 1995). These methods now offer
the possibility of allowing individuals to view real-time measures of
their own regional brain activation (deCharms, 2008). Rapid feed-
back of regional activation level or of distributed patterns of brain
activation might provide a novel means of instructing subjects on
how to modulate their own brain function. Goals of such feedback
include modulation of activity in speciﬁc brain regions in response
to intrinsic or extrinsic cues, as well evaluation of the effects of
various interventions.
Data suggest that subjects can indeed learn volitional control
over a speciﬁc brain region. For example, healthy subjects can
be taught to control brain activity within the anterior insula
(Caria et al., 2007). In another study, both healthy subjects and
patients with chronic pain were able to use real time functional
MRI training to learn to control activation of brain regions
involved in modulation of pain, which was associated with a con-
comitant decrease in pain perception (deCharms et al., 2005). The
long-term goal is to improve patient outcomes by modulating
brain activity in those selected neural circuits that are most related
to the target symptoms.
Assessing neuroplastic capacity and
monitoring circuit reorganization
Although a number of smaller studies appear to promote clinically
relevant neuroplasticity, in most cases compelling evidence from
large studies or clinical trials is still needed. The fundamental need
in harnessing neuroplasticity for clinical applications is to reliably
demonstrate behavioural improvements in human populations.
This goal would be aided by validation of (i) prognostic indicators
to identify those individuals with capacity for neuroplasticity, i.e.
those most likely to respond to an intervention; and (ii) surrogate
markers of efﬁcacy to assist clinical trials. Numerous probes exist
to assess the nervous system in this regard (Endres et al., 2008),
many of which have been discussed above. Transcranial magnetic
stimulation can provide insight into many cortical functions, inhibi-
tory tone, pharmacological effects and neurophysiology, can pro-
duce virtual lesions, and can generate enduring effects on cortical
function. PET can measure a multitude of brain functions, perfu-
sion and metabolism and provide speciﬁc molecular insights. MRI
can provide information on brain structure, function, perfusion,
white matter integrity, tractography and network connectivity.
Connectivity has been discussed above in relation to stroke
(Grefkes et al., 2008; Sharma et al., 2009b), schizophrenia (Balu
and Coyle, 2011) and movement disorders (Johnson et al., 2008).
Emerging functional connectivity MRI methods provide
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tributed networks, such as emotion, motor and cognitive, in par-
allel, and so might be of high value in the future, unifying
concepts across divergent conditions related to neuroplasticity.
Regarding predictors, one approach that might be of particular
merit is the evaluation of reserve, which can be operationalized as
the ability to improve performance given optimized conditions or
training. In clinical practice, treatment of many organ systems is
deﬁned by a measure of organ structure or function rather than
behavioural assessment, such as treatment of hypothyroidism.
Also, treatment is often best prescribed when organ function is
observed in response to a challenge, such as triage of patients
with coronary artery disease in response to exercise or treatment
of asthma based on response to methacholine; a random serum
cortisol does not have nearly the information as the change in
cortisol in response to adrenocorticotropic hormone infusion.
These same principles are being extended to studies of therapies
that promote neuroplasticity. Thus, measuring function (Cramer
et al., 2007c) or injury (Stinear et al., 2007) at baseline or in
response to a brief challenge (Koski et al., 2004) have each
been found in small studies to have utility for predicting response
to subsequent plasticity-promoting therapy.
Surrogate endpoints of clinically relevant neuroplasticity might
help establish the clinical utility of therapies under study. This was
considered above, where many of the candidate methods for ob-
taining such measures were described. One important consider-
ation for a surrogate marker is the extent to which the method
can be directly translated from animal to human studies, as is the
case for some transcranial magnetic stimulation (Oberman et al.,
2010) and MRI methodologies (van Meer and Dijkhuizen, 2010).
Other points are that a surrogate measure has reduced utility
when it is not in the causal pathway of the disease process,
when the therapy selectively affects physiology of the surrogate,
or when the surrogate measure does not fully capture the net
effect of therapy on the clinical outcome (Fleming and DeMets,
1996; Bucher et al., 1999).
Surrogate endpoints are generally easier to measure and stand-
ardize and save time compared with most behavioural endpoints.
Such markers have proved useful in phase II trials to probe bio-
logical activity of a proposed therapy, gain mechanistic insights,
guide features of therapy in ways that behavioural assessment
cannot, inform the decision of whether or not to proceed to
Phase III, or deﬁne a target population (Fleming et al., 1994;
Milot and Cramer, 2008). In the setting of neuroplasticity, a sur-
rogate marker might be useful to demonstrate that behavioural
recovery can be attributed to an anatomical or physiological
change of interest (Segal et al., 2006).
Selected issues in the study of clinical
neuroplasticity
A number of issues complicate the study of neuroplasticity. Many
of these directly impact clinical applications. Disease can affect
imaging biomarkers in numerous ways outside of study hypoth-
eses, such as through the inﬂuence of increased head motion,
reduced attention or concomitant impairments. The caveats
expressed above regarding cautious interpretation of functional
neuroimaging results in the setting of stroke are likely to extend
to many of the neurological conditions characterized by neuroplas-
ticity. Neurological disease and its treatment can affect many fac-
tors impacting functional neuroimaging results, either directly or
indirectly. Examples include effects on attention, intention, pain
threshold, behaviour during the resting state and patient strategy.
Another set of issues pertains to clinical trial design. Crossover
studies are not always possible, as an intervention that promotes
plasticity changes the brain, perhaps in an enduring way, and so
might not allow for an independent assessment of a second inter-
vention after crossover. Concern exists for selection bias. For
example, although published multi-site trial data for constraint-
induced therapy are impressive, a limited proportion of patients
with stroke are eligible (Wolf et al., 2002). Indeed, it is not un-
common for plasticity trials in stroke to screen 40 patients for each
one enrolled (Gladstone et al., 2006). The impairments and limi-
tations of those enrolled may not be representative of the overall
disease population. Also, in many conditions, plasticity evolves
through successive temporal stages and so is time-sensitive; plas-
ticity is in some respects a four-dimensional therapeutic target.
This introduces a need to assess behaviour, biomarkers, treatment
effects and more at speciﬁc time points; for example, plasticity in
patients with the same disease can be quite different when as-
sessed early after a CNS insult versus weeks later. The time course
of some conditions, particularly developmental or degenerative,
suggests a need to observe patients (or therapies) for years to
answer a speciﬁc question related to neuroplasticity. Plasticity stu-
dies are thus particularly vulnerable to effects and biases intro-
duced by subject dropout. However, the use of biomarkers such
as imaging might improve this situation (Holland et al., 2009).
Many factors inﬂuence plasticity under healthy conditions, and
CNS disease only increases the complexity of this situation. As
such, a large number of covariates and their interactions some-
times must be considered. Disease strikes the CNS of each patient
differently; to this point, C. Miller Fisher used to quip that ‘when it
comes to stroke, there isn’t a single common Englishman in all of
London’. Because of these differences, inﬂuences and therapies for
neuroplasticity must have a substantial effect size else large study
populations are needed. In some settings, multi-site cooperative
research study groups may be unavoidable. Studies of plasticity
will beneﬁt from stratifying patients and by advances in methods
to identify biologically distinct subgroups.
This variability also complicates the generalization of ﬁndings.
Generalization can be said to occur when therapy-induced
changes ‘occur over time, persons, and settings, and the effects
of the change...spread to a variety of related behaviours’ (Stokes
and Baer, 1977). Reduced generalization might limit the thera-
peutic impact of plasticity-promoting interventions. Krakauer
(2006) noted that ‘recovery related to spontaneous biological pro-
cesses seems to improve performance across a range of tasks
whereas recovery mediated by training, like learning in healthy
subjects, is more task-speciﬁc’. In response to this, some protocols
can be designed to maximize generalizability (Carey and Matyas,
2005); for example, variable practice increases generalization of
learning to new tasks.
1602 | Brain 2011: 134; 1591–1609 S. C. Cramer et al.Plasticity in the clinical context discussed is generally experience
dependent. Both disease expression and treatment effects are
inﬂuenced by a wide range of experiences, a fact that complicates
study and harnessing of neuroplasticity. Measuring prior experi-
ence can be difﬁcult, for example, in the setting of psychosis or
dementia. Controlling future experience can be equally difﬁcult,
such as for a patient given a stem cell injection, the impact of
which will be inﬂuenced by amount/type of subsequent rehabili-
tation therapy. Differences in health-care delivery systems across
countries further complicate this issue. Indeed, it can be difﬁcult to
simply measure the amount of relevant experience among partici-
pants in a clinical trial of a plasticity-promoting therapy. This is not
a trivial issue; in one recent, large, multi-centre, randomized, con-
trolled trial of robotic therapy to improve arm function after
stroke, 73% of participants were receiving some form of rehabili-
tation therapy outside of study procedures at the time of enrol-
ment (Lo et al., 2010), and most continued this therapy during the
trial. In many ways, the experience that accompanies and shapes a
therapy promoting neuroplasticity is akin to the common practice
of adding an adjuvant (such as a carrier protein) to achieve max-
imum efﬁcacy for many vaccines.
As with many other neuroscience areas, translating neuroplasti-
city ﬁndings from animal models to humans can be difﬁcult.
Compared with human counterparts, studied animals usually
have a younger relative age, more homogenous injury and lower
frequency of comorbid conditions. Rodents are often studied but
these animals are quadrupeds with prominent reliance on vibrissae,
are housed in social conditions that often do not well model the
human experience, and have white matter that constitutes 14% of
brain volume compared with 50% in humans (Cramer, 2003;
Goldberg and Ransom, 2003). The need has been emphasized
for direct and enduring interactions between basic and clinical
researchers to maximize translational productivity.
Conclusions and future
directions
Neuroplasticity plays a signiﬁcant functional and ameliorative role
across a wide spectrum of brain diseases as well as in normal
ageing and health. Measures of plasticity can provide insights
into disease pathogenesis, improve treatment strategies and help
identify substrates of treatment effects.
This report describes a number of principles of neuroplasticity
common across several forms of CNS disease. Many forms of
neuroplasticity can be ongoing in parallel. Neuroplasticity is
often experience dependent, time-sensitive and strongly inﬂu-
enced by features of environment. Motivation and attention can
be critical modulators of plasticity. Skills training can improve be-
havioural outcomes on the backbone of neuroplasticity; in many
cases, maintenance of behavioural gains depends on continued
therapeutic exposure. Many covariates inﬂuence neuroplasticity.
Neuroplasticity does not always have a positive impact on behav-
ioural status and can result in negative consequences in some
cases. Note too that there are many important differences be-
tween CNS disorders in neuroplasticity ﬁndings, such as the
temporal course and spatial distribution of the CNS disease that
incites plasticity, the extent to which ageing effects interact with
plasticity, the extent to which plasticity itself directly inﬂuences
disease pathogenesis, and the degree to which relevant animal
models are available for the study of plasticity.
Although a number of promising neuroplasticity-based interven-
tions have been identiﬁed or are under study, many questions
remain. Some of these have been described above, such as
issues related to clinical trial methodology. In many cases, funda-
mental issues such as optimal therapy parameters and patient
population require much more clariﬁcation, which might require
increased reliance on multi-site research cooperative groups.
Directions for future research might include tailoring
plasticity-based therapies based on individual patient measure-
ments such as functional status of residual brain circuits or distri-
bution of disease. High-throughput methods are needed to screen
potential plasticity-promoting interventions within speciﬁc net-
works. Most commonly, therapies under study to promote neuro-
plasticity have been examined one at a time, but with greater
experience and understanding these therapies can be examined
in combination, e.g. task-speciﬁc training coupled with stem cell
therapy. An understanding of treatment mechanisms at every level
will facilitate the development of preventive and therapeutic inter-
ventions. Animal models that replicate the complexity of disease
mechanisms over time are needed. Ideally, such models will attend
to human risk factors such as age, comorbidities and variation in
patterns of pathology, and will employ ecologically valid activities.
While rodent studies are well suited to investigations of
cellular-molecular mechanisms, non-human primate studies may
be more appropriate for understanding circuit-level changes.
Because underlying biological vulnerabilities are critical for many
diseases, databases determining associated genetic polymorphisms
(Pearson-Fuhrhop et al., 2009) might facilitate the development of
therapies aimed at altering protein functions to regulate neuroplas-
ticity. Improved means to access the brain might allow improved
CNS signal measurement as well as increased reliance on direct
brain–computer interactions (Kurzweil, 2005).
For many CNS conditions, a deeper understanding of age ef-
fects on neuroplasticity is needed. Insight into critical periods, the
mechanisms by which they inﬂuence circuit development, and the
forces that cause them to end may be fruitful for maximizing
neuroplasticity-based treatments in adults. Understanding more
fully the interaction between ageing and plasticity mechanisms
might be particularly useful for reducing disability in older
populations.
Valid assessments of circuit engagement and reorganization,
including early surrogate markers capable of predicting and moni-
toring treatment response, are needed. A greater understanding of
what these surrogate markers reﬂect at the cellular–molecular level
is critical. Standardization of data collection and publication would
facilitate the sharing and accumulation of knowledge across stu-
dies and diseases. Through greater sharing of end points and study
designs across conditions related to neuroplasticity, a higher
understanding can emerge. Parallel studies in animals and
humans that explicitly examine relationships between circuit-level
and cellular–molecular changes may be particularly helpful. Finally,
assessments of outcome should include not only behavioural and
Harnessing neuroplasticity Brain 2011: 134; 1591–1609 | 1603neural measurements, but also community function, quality of life,
and the subjective experience of the individual.
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